Nixon Peabody Says Intel's Tapped Out In Biotech Stock Row
Nixon Peabody LLP continued Friday to push back against Neogenix Oncology Inc.'s demands that the firm produce more intel on stock fees in the cancer treatment developer's malpractice suit, telling a...To view the full article, register now.
Already a subscriber? Click here to view full article